SEC Form 4 · accession 0001209191-17-066618
CELGENE CORP /DE/ · CELG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Terrie Curran
Officer — See remarks
Period of report
Dec 19, 2017
Accepted (ET)
Dec 20, 2017 · 4:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000816284
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 19, 2017 | M | 1,765 | $0.00 | A | 5,690 | D | |
| Common Stock | Dec 19, 2017 | F | 683 | $107.06 | D | 5,007 | D | |
| Common Stock | holding | — | — | — | 599 | I | 401(k) Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF3,F1,F2 | — | Dec 19, 2017 | M | 1,765 | D | — | — | Common Stock | 1,765 | 0 | D |
Explanation of responses
- F1All of the restricted stock units granted to the reporting person on December 19, 2014 vested and settled for shares of the Company's common stock.
- F2Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
- F3The restricted stock units were issued pursuant to The Celgene Corporation 2017 Stock Incentive Plan.
Remarks
President, Inflammation & Immunology